Abstract
mUC is an aggressive disease with limited overall survival. HER2 overexpression is associated with poor prognosis and occurs in a significant number of patients (pts) with mUC. HER2-targeted ADCs represent a promising strategy in mUC, with multiple ongoing clinical trials. We aimed to realize a systematic review of efficacy and toxicity of anti-HER2 ADCs in mUC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
